Document Type

Fact Sheet

Publication Date

2024

Abstract

Leveraging our experience developing the monthly dapivirine vaginal ring (DVR or “PrEP ring”), which received a positive opinion from the European Medicines Agency in 2020 for women’s HIV risk reduction, the Population Council is developing a 3-month multipurpose vaginal ring to help women protect against both HIV and unintended pregnancy. This ring is designed to slowly release the antiretroviral (ARV) drug, dapivirine and the contraceptive hormone, levonorgestrel.

Language

English

Share

COinS